AWS
AUPH icon

Atria Wealth Solutions’s Aurinia Pharmaceuticals AUPH Stock Holding History

Atria Wealth Solutions’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$75.9K Hold
10,000
– – ﹤0.01% 1443
2025
Q1 		$80.4K Sell
10,000
-5,000
-33% -$40.5K ﹤0.01% 1804
2024
Q4 		$135K Buy
+15,000
New +$122K ﹤0.01% 1877

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Atria Wealth Solutions's AUPH Position: Q2 2025 in Review

Atria Wealth Solutions held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2025 at 10,000 shares worth $75.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Atria Wealth Solutions first reported a position in AUPH in Q4 2024 and has held it in 3 quarters since. The position peaked at $135K in Q4 2024. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Atria Wealth Solutions held 10,000 shares of Aurinia Pharmaceuticals worth $75.9K as of Q2 2025.
  • Atria Wealth Solutions left its Aurinia Pharmaceuticals share count unchanged in Q2 2025.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Atria Wealth Solutions's portfolio in Q2 2025, its #1443 holding.
  • Atria Wealth Solutions first reported a position in Aurinia Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Atria Wealth Solutions's Aurinia Pharmaceuticals position peaked at $135K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.